Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders

Autism Spectrum Disorders Clinical Trial

— Autisemo  

Official title:

Dialectical Behavior Therapy for Adults With Autism Spectrum Disorders Without Intellectual Disability: a Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04737707
• Other study ID #: 8108
• Status: Recruiting
• Phase: N/A
• Start date: April 16, 2021
• Est. completion date: September 1, 2024

Study information

• Verified date: August 2023
• Source: University Hospital, Strasbourg, France
• Contact: Luisa WEINER, MD
• Phone: 03 88 11 65 11
• Email: weiner.l[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dialectical Behavior Therapy (DBT; Linehan, 1993) effectively diminishes emotion dysregulation and self-harm behaviors in a number of disorders. However, to our knowledge, no studies have investigated the efficacy of DBT to treat emotional dysregulation associated with self-harm and suicidal behaviors in adults with ASD without intellectual disability. This randomized controlled study trial aims to assess the efficacy of a 5-month DBT intervention in adults with ASD without intellectual disability who present with self-harm and/or suicidal behaviors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years old
• ASD diagnosis according to the DSM-5
• IQ = 70
• Suicidal ideas, suicidal attempts and/or self-harm behaviors 6 months prior to the inclusion
• Able to understand and consent to the research aims
• Membership in a health insurance fund

Exclusion Criteria:

• complete hospitalization
• ongoing CBT or DBT
• past DBT
• schizophrenia disorders
• under guardianship

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autism Spectrum Disorders
• Autistic Disorder
• Child Development Disorders, Pervasive

Intervention

Other:
• Dialectical Behavior Therapy (DBT)
Dialectical Behavior Therapy (DBT)

Locations

Country	Name	City	State
France	Service de psychiatrie	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difficulties in Emotion Regulation Scale (DERS)	The minimum value of the DERS scale is 0 and the maximum is 180. The higher the scores, the more severe the deregulation.	baseline
Primary	Difficulties in Emotion Regulation Scale (DERS)	The minimum value of the DERS scale is 0 and the maximum is 180. The higher the scores, the more severe the deregulation.	at the end of therapy (5 months)
Primary	Difficulties in Emotion Regulation Scale (DERS)	The minimum value of the DERS scale is 0 and the maximum is 180. The higher the scores, the more severe the deregulation.	11 months follow-up